Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sanofi Licenses Ligand’s Captisol Technology | Contract Pharma

What are you searching for?

Sign in
Breaking News

Sanofi Licenses Ligand’s Captisol Technology

Will use Captisol in the development and commercialization of cancer therapy SAR-125844

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ligand Pharmaceuticals Inc. has entered into a global license and supply agreement with Sanofi to use Captisol in the development and commercialization of SAR-125844, a potent MET kinase inhibitor inPhase Idevelopment in advanced/refractory solid tumors.
 
Ligand will be eligible to receive potential milestone payments, royalties on sales and revenue from Captisol material sales. Sanofi will be responsible for all costs related to the program.
 
“This represents the progression and expansion of our relationship with Sanofi as they continue to make progress on SAR-125844, a novel, selective MET kinase inhibitor,” said John Higgins, president and chief executive officer of Ligand. “Captisol continues to bring significant value to our partners’ programs and shows great promise in enabling compounds in oncology, CNS, anti-infectives and many other therapy areas.”
 
Captisol is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled seven FDA-approved products, including Amgen’s Kyprolis, Baxter’s Nexteroneand Merck’s NOXAFIL IV.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics